1. Introduction
Positron emission tomography/computed tomography (PET/CT) with the tracer 18 F-fluorodeoxyglucose ( 18 F-FDG) is a powerful diagnostic tool in multiple myeloma (MM) for the detection of medullary and extramedullary disease (EMD), a reliable predictor of survival as well as the modality for treatment response evaluation [ 1 , 2 , 3 , 4 , 5 ]. According to the latest update of the International Myeloma Working Group (IMWG), the detection of one or more osteolytic lesions on CT or PET/CT fulfills the criteria of bone disease in patients with bone marrow plasma cell infiltration of ≥10% or histologically proven plasmocytoma and, therefore, of symptomatic MM requiring treatment [ 5 ].
However, 18 F-FDG PET/CT carries some limitations. Firstly, its sensitivity in particular for detection of diffuse bone marrow infiltration and skull lesions is relatively poor, with the incidence of PET false-negativity reaching 11%, a finding attributed mainly to the significantly lower expression of the gene coding for hexokinase-2, which catalyzes the first step of glycolysis [ 6 ]. Moreover, 18 F-FDG, as a glucose analog, is generally restricted in oncological imaging by both false-positive (inflammation, post-surgical areas, metallic implants, recent use of chemotherapy, fractures, etc.) and false-negative results (hyperglycemia, recent administration of high-dose steroids, etc.) [ 7 , 8 ]. Further, the lack of widely applied criteria for image interpretation of 18 F-FDG PET/CT in MM leads to a rather poor interobserver reproducibility in scan interpretation, a recently addressed issue [ 9 ]. These limitations of 18 F-FDG as a biomarker of MM render the development of other more sensitive and specific PET tracers, potentially targeting different molecular pathways, necessary.
Sodium fluoride ( 18 F-NaF) is another PET tracer used for skeletal imaging. The bone uptake of 18 F-NaF reflects regional blood flow, osteoblastic activity and bone turnover [ 10 , 11 , 12 ]. 18 F-NaF PET/CT is evolving as a highly sensitive imaging modality of bone reconstruction, with potential indications in a wide range of bone disease [ 13 , 14 , 15 ]. Particularly in MM, the use of the radiopharmaceutical can be theoretically justified by the fact that bone disease is a major cause of morbidity and mortality, and that practically all MM patients develop bone involvement during the course of the disease [ 5 ]. Indeed, 18 F-NaF PET/CT has been applied in several studies of MM with results ranging from rather discouraging [ 16 , 17 , 18 , 19 ] to promising [ 20 , 21 , 22 , 23 ]. In this context, the role of 18 F-NaF in MM is yet to be clarified.
With the current prospective study, we investigated for the first time the prognostic significance of qualitative and quantitative parameters derived from dynamic and static 18 F-NaF PET/CT in MM. We compared findings from 18 F-NaF PET/CT with established factors of high-risk disease, like cytogenetic abnormalities, as well as bone marrow plasma cell infiltration rate, and analyzed the impact on progression-free survival (PFS) after autologous stem cell transplantation (ASCT) in patients with newly diagnosed, symptomatic MM. A comparison with respective findings derived from 18 F-FDG PET/CT examinations, performed one day before, in the same cohort was also made.
2. Materials and Methods
2.1. Patients
Forty-seven patients (31 male, 16 female; median age 59.9 years) with previously untreated, symptomatic MM based on the criteria established by the IMWG (2003) were included in the study [ 24 ]. All patients underwent high-dose chemotherapy (HDT) followed by ASCT. Twenty-two patients (45.8%) were enrolled in the prospective GMMG MM5 phase III trial that compared two different bortezomib-based induction therapies, followed by ASCT and lenalidomide consolidation as well as maintenance therapy for two years or until complete response [ 25 ]. Twenty-five patients (53.2%) were treated outside the MM5 trial with comparable treatment regimens and ASCT. The same cohort has been evaluated in a previous publication of our group in a different analysis with regard to 18 F-FDG PET/CT [ 26 ]. Neither diabetic patients nor patients under steroid therapy at the time of PET/CT scanning were included in our analysis. Patients gave written informed consent after the study was fully explained to them. Our study was conducted in accordance to the declaration of Helsinki, and was approved by the ethical committee of the University of Heidelberg (S-076/2010) and the Federal Agency of Radiation Protection in Germany (“Bundesamt für Strahlenschutz”).
2.2. PET/CT Data Acquisition
All patients underwent 18 F-NaF PET/CT. Data acquisition consisted of two parts: the dynamic part (dPET/CT studies) and the static part (whole-body PET/CT). dPET/CT studies were performed over the lower abdomen and the pelvic area after intravenous administration of maximum 250 MBq 18 F-NaF for 60 min using a 24-frame protocol (10 frames of 30 s, 5 frames of 60 s, 5 frames of 120 s and 4 frames of 600 s). Whole-body, static imaging was performed in all patients with an image duration of 2 min per bed position for the emission scans after the end of the dynamic acquisition. A dedicated PET/CT system (Biograph mCT, S128, Siemens Co., Erlangen, Germany) with an axial field of view of 21.6 cm with TruePoint and TrueV, operated in a three-dimensional mode was used. The system allows the simultaneous acquisition of 56 transversal slices (1 bed position) with a theoretical slice thickness of 2.036 × 2.036 × 4 mm [ 27 ]. A low-dose attenuation CT (120 kV, 30 mA) was used for attenuation correction of the dynamic emission PET data and for image fusion. A second low-dose CT (120 kV, 30 mA) was performed after the end of the dynamic series covering the area from the skull to the feet. All PET images were attenuation corrected and an image matrix of 400 × 400 pixels was used for iterative image reconstruction. Iterative image reconstruction was based on the ordered subset expectation maximization algorithm (OSEM) with 2 iterations and 21 subsets as well as time of flight (TOF).
2.3. PET/CT Data Analysis
Data analysis consisted of qualitative analysis of the PET/CT scans, semi-quantitative evaluation based on standardized uptake value (SUV) calculations, and quantitative analysis of the dynamic 18 F-NaF PET data.
Qualitative analysis was based on visual assessment of the PET/CT scans. Skeletal foci of enhanced 18 F-NaF uptake were classified as MM, based on the results of the underlying low-dose CT and the 18 F-FDG PET/CT performed one day before, which served as reference. Briefly, only those 18 F-NaF positive skeletal lesions that corresponded to lytic lesions on CT or to respective 18 F-FDG-positive skeletal lesions, for which another benign (e.g., degenerative, posttraumatic) etiology was excluded, were considered suggestive of MM [ 16 , 18 , 19 ].
Semi-quantitative evaluation was based on volumes of interest (VOIs) and on subsequent calculation of SUV values. VOIs were drawn with an isocontour mode (pseudo-snake) [ 28 ] and were placed over reference tissue as well as over the hottest, focal MM lesion in each patient, if present. The iliac bone, if without focal tracer enhancement, served as reference tissue. In cases of focal lesions in the iliac bone, the same bone of the opposite side served this purpose.
Quantitative evaluation of the dynamic 18 F-NaF PET/CT data of the lower abdomen and the pelvic area was also performed in the hottest MM lesion and in reference tissue (iliac bone). The analysis was performed using a dedicated software (PMOD Technologies Ltd., Zürich, Switzerland) and based on a two-tissue compartment model with a blood component (fractional blood volume, V B ) with methods already reported in literature and performed previously by our group [ 16 , 18 , 19 , 29 , 30 , 31 ]. The input function was retrieved from PET/CT data. Although the accurate measurement of the input function requires arterial blood sampling, it can be retrieved relatively simplified and non-invasively from the image data with good accuracy [ 32 ]. In particular, the mean value of the VOI data from a large arterial vessel of the lower abdomen/pelvic area (descending aorta or common iliac artery) was used. A vessel VOI consisted of at least seven ROIs in sequential PET/CT images. The recovery coefficient was 0.85 for a vessel diameter of 8 mm. For the input function, we used vessels with no signs of atherosclerotic plaques in CT for the measurements. A limitation of compartment modeling is that the assessment of the transport rates can be operator dependent. The reason is that these models use an iterative fitting to calculate the least squares between measured and model data, which may lead to overfitting problems. Noise in the time–activity curves (TACs) and, in particular, inappropriate input (TACs) have an impact on the assessed rates. A robust solution to overcome these problems has been published by a group, based on machine learning approaches and a large oncological reference database [ 31 , 33 ].
Briefly, in the case of 18 F-NaF, the two-tissue compartment model consists of the vascular compartment (plasma), the extravascular bone compartment, and the bone mineral compartment. Application of this model leads to the extraction of the kinetic parameters K 1 , k 2 , k 3 and k 4 as well as influx (K i ). The rate constants K 1 and k 2 describe fluoride ion clearance from plasma to the extravascular compartment, reflecting the exchange of the ions between plasma and bone interstitial fluid. The parameters k 3 and k 4 describe the exchange of fluoride with hydroxyl groups of hydroxyapatite crystal of the bone, representing the formation of fluorapatite and the opposite. Influx (K i ) is derived from the equation = (K 1 × k 3 )/(k 2 + k 3 ) and reflects the net clearance of 18 F-NaF to the bone mineral compartment and, presumably, represents the bone remodeling rate [ 12 ]. V B reflects the fraction of blood within the VOI.
In addition to compartment modeling, fractal analysis, a non-compartment model, was used in order to calculate the parameter of heterogeneity and complexity, expressed by a non-integer value, so-called fractal dimension (FD). FD is calculated for the time–activity data in each individual voxel of a VOI and represents tissue heterogeneity based on the box counting procedure of chaos theory. The values of FD vary from 0 to 2, showing the more deterministic or chaotic distribution of the tracer activity respectively [ 34 ].
2.4. Clinical Parameters, Bone Marrow Plasma Cell Infiltration and Fluorescence In Situ Hybridization
All patients included in the study received bone marrow aspirates or biopsies performed within four weeks around the 18 F-NaF PET/CT examination. Percentage of bone marrow infiltration by malignant plasma cells was assessed via light microscope from Giemsa-stained bone-marrow smears [ 35 ]. The infiltration rate represents the number of plasma cell in comparison to all nucleated, hematopoietic cells in the bone marrow. For the definition of high-risk disease, the Revised International Staging System (R-ISS) score was defined before start of therapy. Based on this prognostic system, stage R-ISS I included patients of ISS stage I (serum β2-microglobulin level < 3.5 mg/L and serum albumin level ≥ 3.5 g/dL), no high-risk chromosomal abnormalities, and normal lactate dehydrogenase (LDH) level; stage R-ISS III included ISS stage III (serum β2-microglobulin level > 5.5 mg/L) and high-risk chromosomal abnormalities [del(17p) and/or t(4;14) and/or t(14;16)] or high LDH level; stage R-ISS II included all the other possible combinations [ 36 ]. Fluorescence in situ hybridization (FISH) was performed, as described previously [ 37 ], on CD138-purified plasma cells using the following probes: 1q21, 5p15, 5q35, 8p21, 9q34, 11q22.3, 13q14, 15q22, 17p13, and 19q13. We also investigated immunoglobulin H (IgH) translocations using an IgH break-apart probe as well as probes for t(11;14), t(4;14) and t(14;16).
2.5. Statistical Analysis
Spearman correlation analysis was performed to investigate the correlation between quantitative PET parameters, since some of these parameters showed a skewed distribution. PFS was measured from the date of start of treatment until disease progression or death from any cause. Kaplan–Meier estimates were generated and median PFS estimated. Median follow-up time was determined by inverse Kaplan–Meier estimation. For univariate comparison of PFS, a log-rank test was used. Multivariate Cox proportional hazards regression analysis for all 18 F-NaF PET parameters adjusting for different risk groups determined at start of therapy was applied. Maximally selected rank statistics were used to identify the optimal cut point of quantitative covariables used for dichotomization of the cohort with respect to PFS. Statistical analysis was performed using R version 3.6.1 (The R Foundation for Statistical Computing 2019) and R packages survival and maxstat. The results were considered significant for p values less than 0.05 ( p < 0.05).
3. Results
3.1. Patient Cohort
The plasma cell infiltration, as derived from bone marrow aspirates or biopsies from the iliac crest, ranged between 1% and 92%, with a mean value of 40% (median = 32%). Cytogenetic data were available in 40 patients (85%), with high-risk cytogenetic abnormalities being detected in 8/40 (20%) of them. A combination of the ISS and cytogenetic data was available in 36 patients. Based on this, 14 patients were classified in the R-ISS-1 group (38.9%), 20 patients in the R-ISS-2 group (55.5%), and two patients in the R-ISS-3 group (5.6%) ( Table 1 ).
3.2. 18 F-NaF PET/CT Findings
Twenty-seven patients (57%) had a pathologic 18 F-NaF PET/CT, while the remaining 20 patients (43%) had no pathologic findings on PET/CT ( Figure 1 ). No EMD was detected with this tracer in the cohort. Patients with a pathologic 18 F-NaF pattern had a median bone marrow plasma cell infiltration of 41.0% (mean = 45.7), compared to a median of 19.5% (mean = 30.5%) of those with no pathologic findings on PET/CT ( p = 0.07). Regarding relation between PET distribution and results of cytogenetic analysis it was found that 5/8 patients (62.5%) with high-risk abnormalities demonstrated a pathologic PET pattern, while 3/8 patients (37.5%) were PET negative. Respectively, 19/32 (59%) patients with standard cytogenetic risk had a pathologic PET, while 13 of them (41%) were PET negative.
As mentioned above, semi-quantitative (based on SUV calculations) and quantitative analyses of the 18 F-NaF PET data (based on two-tissue compartment modeling and fractal analysis) were performed both in reference tissue (os ilium) and in the hottest focal MM lesion in each patient with such lesions. The descriptive statistics of these calculations are presented in Table 2 . No statistically significant differences were observed between patients of different ISS and R-ISS groups regarding any 18 F-NaF PET parameter.
3.3. Correlation between 18 F-NaF PET/CT Parameters, Bone Marrow Plasma Cell Infiltration and Cytogenetics
Exploratory correlation analysis between the quantitative PET parameters and bone marrow plasma cell infiltration revealed that in reference tissue, SUV average and K 1 correlated moderately but significantly with bone marrow infiltration by malignant plasma cells (r = 0.30 and r = 0.35, respectively). In contrast, no significant correlation was observed with all other parameters from reference tissue as well as those from MM lesions. Moreover, no statistically significant differences were observed between patients with high-risk abnormalities and those with standard cytogenetic risk regarding any PET parameter both in reference tissue and MM lesions, with p values ranging between 0.14 (SUV max of reference tissue) and 0.94 (K 1 of MM lesions).
3.4. Correlation between 18 F-NaF PET/CT and PFS
Based on the visual/qualitative evaluation of the whole-body PET/CT scans, we found that patients with a pathologic 18 F-NaF PET/CT demonstrated a median PFS of 36.2 months, compared to 55.6 months in the group of patients with a physiologic (negative) 18 F-NaF distribution pattern ( p = 0.02) ( Figure 2 ).
Quantitative PET parameters in reference tissue and MM lesions were dichotomized at the median to investigate their effect on PFS. However, no statistically significant differences in PFS were observed between patients with parameters below the median versus patients with values above the median. Moreover, no optimal cut-offs for these parameters regarding PFS prediction could be identified using maximally selected rank statistics. Furthermore, multivariable Cox proportional hazards regression analysis for all 18 F-NaF PET parameters adjusting for different risk groups was also performed and revealed no significant impact on PFS.
A survival analysis was also performed for quantitative, dynamic 18 F-FDG PET/CT. Similarly to 18 F-NaF PET, quantitative 18 F-FDG PET parameters in reference tissue and MM lesions were also dichotomized at the median to investigate their effect on PFS. According to this, the PFS of patients with parameters SUV max ( p = 0.01), V B ( p = 0.02), k 3 ( p = 0.04) and influx ( p = 0.006) from reference tissue as well as SUV average from MM lesions ( p = 0.02) above the median value was significantly shorter compared to patients with respective values below the median ( Figure 3 and Figure 4 ). The respective descriptive statistics for 18 F-FDG PET parameters are presented in a previous publication of our group [ 26 ].
4. Discussion
The determination of the extent of bone disease is one of the most challenging tasks in MM diagnostics, with implications in patient quality of life and prognosis. In this context, the role of PET/CT with the tracer 18 F-FDG has been highly explored and upgraded, as reflected by the increasing amount of literature published in the field [ 1 , 2 , 3 , 4 , 5 ]. However, despite its nowadays recognized role in MM diagnosis, prognosis and treatment response evaluation, 18 F-FDG PET/CT is far from being considered an optimal biomarker for the disease, due to its several limitations.
In an attempt to overcome these limitations of 18 F-FDG as an imaging biomarker of MM, several other PET tracers have been proposed and tested in smaller patient studies with this malignancy. For example, 11 C-methionine, an aminoacidic PET tracer mainly employed in the diagnosis of central nervous system (CNS) tumors, has been shown to be superior over 18 F-FDG for staging and re-staging of both intra- and extramedullary MM lesions [ 38 , 39 , 40 ], and can moreover highlight more rare and radiologically challenging sites of EMD such as the CNS [ 41 ]. 68 Ga-pentixafor, a radiolabeled peptide with high affinity for chemokine receptor 4 (CXCR4), which is involved in myeloma cell homing, bone marrow retention, angiogenesis and metastasis, has shown very promising results regarding both its diagnostic performance [ 42 , 43 ] and its potential application as a theranostic agent, identifying candidates suitable for CXCR4-directed therapies with β-emitting radionuclides such as lutetium-177 ( 177 Lu). The first results of this approach have demonstrated that this form of 68 Ga-pentixafor-tailored endoradiotherapy is feasible and successful even at an advanced MM stage [ 44 ]. However, further studies in large patient cohorts are needed to assess the clinical potential of these tracers within the MM work-up.
18 F-NaF is a very sensitive and reproducible PET tracer for the quantification of bone metabolism [ 10 , 11 , 12 ]. In recent years, several studies have investigated the potential role of 18 F-NaF PET/CT in detection of MM bone lesions with rather controversial results [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. At present, PET/CT with 18 F-NaF, similar to all non- 18 F-FDG tracers, is not part of the diagnostic algorithm of MM.
Our work aimed at comparing findings of 18 F-NaF PET/CT with recognized biomarkers of MM as well as investigating the prognostic significance of this imaging modality in the disease. Due to the known high incidence of false-positive findings on 18 F-NaF, as a highly sensitive imaging agent of bone reconstruction, the characterization of a 18 F-NaF PET scan as pathologic was based on the presence of focal, 18 F-NaF avid lesions only after comparison with the underlying low-dose CT and the 18 F-FDG PET/CT performed one day before, which are recognized biomarkers of bone disease in MM and thus served as reference. Firstly, a comparison of the 18 F-NaF PET/CT findings with bone marrow plasma cell infiltration was performed. We found that patients with a pathologic 18 F-NaF PET/CT had a non-significantly higher bone marrow plasma cell infiltration rate than those with a normal PET/CT scan. Correlation analysis revealed that in reference skeleton, the intensity of tracer uptake, reflected by SUV average , and fluoride ion clearance from plasma to the extravascular compartment, reflected by K 1 , correlated moderately but significantly with bone marrow infiltration by malignant plasma cells. Similar results were obtained in a study by our group comparing the tracer 18 F-FDG with results of bone marrow infiltration [ 34 ]. That study had also documented a moderate, significant correlation of the parameters SUV average and K 1 with the rate of infiltration by malignant plasma cells in reference tissue (bone marrow of the iliac bone). However, significant correlations were also observed with other quantitative 18 F-FDG PET parameters such as SUV max , influx (K i ) and FD, which was not the case in the present study.
We further compared 18 F-NaF PET/CT findings with the results of cytogenetic analysis. A total of 62.5% of the patients with high-risk abnormalities had a pathologic PET scan and 37.5% of them were PET negative, with no significant differences between patients with high-risk abnormalities and those with standard cytogenetic risk.
EMD is another feature recognized to adversely affect survival in MM [ 1 , 45 , 46 ]. Despite the presence of four patients with known EMD in this cohort based on 18 F-FDG PET/CT [ 26 ], none could be identified by means of 18 F-NaF PET/CT, highlighting a disadvantage of the tracer.
The main focus of the present study was the investigation of the potentially predictive role of 18 F-NaF PET/CT on MM survival. Survival analysis revealed that a pathologic 18 F-NaF PET/CT scan is associated with a statistically significantly shorter PFS than a normal one. However, no association was observed between any 18 F-NaF parameter, derived either from reference tissue or MM lesions and PFS. In comparison, the respective analysis in the same patient cohort with the tracer 18 F-FDG revealed a significant adverse effect of the parameters SUV max , V B , k 3 and influx from reference tissue as well as SUV average from MM lesions on patient survival. These findings on 18 F-FDG PET/CT are actually the outcome of an updated survival analysis in the same patient cohort previously studied and published by our group in 2019 [ 26 ].
These findings are not surprising regarding the performance of 18 F-NaF PET/CT in MM. Previous studies from our and other groups had shown that the detection rate of MM bone lesions by 18 F-NaF PET imaging was lower than that of 18 F-FDG PET, while specificity issues were also raised due to the nature of the tracer [ 16 , 17 , 47 ]. In particular, in a study of 60 MM patients examined with both 18 F-FDG PET/CT and 18 F-NaF PET/CT, the latter could detect only 39% of the myeloma lesions detected by 18 F-FDG PET/CT [ 16 ]. In line with this, Ak et al. showed that 18 F-NaF PET/CT detected 57 of the 128 MM lesions demonstrated on 18 F-FDG PET/CT in a group of 26 patients. In addition, 135 bone lesions attributed to fractures and degenerative changes were depicted with 18 F-NaF PET/CT, stressing the low specificity of the tracer [ 17 ]. Further, in a cohort of 30 patients (10 each with monoclonal gammopathy of unknown significance (MGUS), smoldering multiple myeloma (SMM) and MM) evaluated with conventional skeletal surveys, 18 F-FDG PET/CT, 18 F-NaF PET/CT, and dynamic contrast enhanced MRI (DCE-MRI), 18 F-NaF PET provided no additional information in addition to that already present on the CT component [ 47 ]. The explanation for the low sensitivity of 18 F-NaF PET in detection of MM bone disease can be found in the nature of both the myeloma lesions and the radiotracer: myeloma bone disease is purely osteolytic with absent or minimal osteoblastic activity [ 48 ]. However, the uptake of 18 F-NaF reflects osteoblastic activity, resulting in lack of depiction of several lytic lesions on PET imaging. The same mechanism can also explain the limited specificity of 18 F-NaF PET. Any cause of bone reconstruction and/or newly mineralizing bone, irrelevant of its etiology, leads to increased accumulation of 18 F-NaF, resulting in a high incidence of false-positive findings, such as in traumatic or degenerative bone lesions [ 16 , 18 ].
Interestingly, some recent studies have assessed the role of 18 F-NaF PET/CT in treatment response assessment of MM with controversial results. Wang et al. studied with 18 F-NaF PET/CT six patients from a phase I clinical trial of a monoclonal antibody targeting the glycoprotein DKK1 (Dickkopf-1) before study entry and after completing six cycles of therapy. The changes in SUV average in the lumbar spine and the left hip were calculated, revealing a statistically significant increase as response to treatment [ 21 ]. In contrast, Nakuz et al. reported on a statistically significant SUV max decrease in MM lesions in seven patients examined with 18 F-NaF PET/CT before and after treatment. All patients of that cohort showed either a very good partial response or complete response according to the IMWG guidelines. However, they were treated with different anticancer regimens, including radiotherapy, immunochemotherapy and ASCT, and had varying times of follow-up scans [ 49 ]. A significant drawback of both studies is the very low number of patients included. In the largest cohort of MM patients ( n = 29) studied with both 18 F-FDG PET/CT and 18 F-NaF PET/CT before and after HDT/ASCT, 18 F-NaF yielded rather disappointing results both in initial evaluation of disease extent and in the assessment of treatment response. Baseline 18 F-NaF PET/CT was negative in 14% of the 18 F-FDG PET/CT-positive MM patients, in total depicting only 43% of the 18 F-FDG-positive lesions. Regarding follow-up studies, 18 F-NaF PET/CT showed persistence of the majority (82%) of the baseline 18 F-NaF positive MM lesions after treatment, despite the fact that 65% of them had turned 18 F-FDG negative as response to treatment. It is of note that in that study, SUV values as well as the kinetic parameters K 1 and influx from reference skeleton demonstrated a significant decrease after therapy, despite the persistence of most focal MM lesions [ 19 ]. Most recently, Zadeh et al. followed, with 18 F-NaF PET/CT, two groups of MM patients undergoing different therapeutic regimens: the first received HDT/ASCT ( n = 19 patients), and the second received conventional chemotherapy ( n = 11 patients). The authors applied a CT-based algorithm to segment the bones, and the global mean SUV of the whole bone, pelvis and femoral neck was calculated. The main finding of this study was that the global 18 F-NaF uptake significantly decreased after treatment in the group treated with HDT/ASCT, but not in the group receiving conventional chemotherapy. However, the two patient groups had different follow-up periods (8 weeks vs. 2 weeks), rendering direct comparison between them difficult [ 50 ]. The results of the aforementioned studies do not allow for any robust conclusions to be drawn regarding the potential role of 18 F-NaF PET/CT in treatment assessment of MM.
The major limitation of the current study is the relatively small number of patients studied. This can be, however, justified, given the longer acquisition time of dynamic PET scanning, which is a necessity if quantitative/kinetic data are to be acquired. Other limitations include the lack of histological confirmation of the 18 F-NaF avid focal lesions as well as the fact that dynamic sequences were performed only in the lower abdomen and the pelvis. The recent advent of new PET/CT scanners, which allow dynamic studies over several bed positions by using a continuous movement, will facilitate the use of dynamic PET protocols and reduce the acquisition time [ 51 ]. Finally, we focused on the predictive value of baseline imaging findings and patient characteristics before start of treatment, without performing further analyses including response to the applied treatment, e.g., induction therapy, ASCT or even best response after initial imaging, as it was not topic of this study.
5. Conclusions
In an attempt to investigate for the first time the prognostic significance of 18 F-NaF PET/CT in patients with newly diagnosed, symptomatic MM, we compared findings derived from dynamic and static PET/CT with established factors of high-risk disease, including bone marrow plasma cell infiltration rate and cytogenetic abnormalities, and analyzed the impact on PFS. Apart from a moderate, significant correlation of SUV average and K 1 in reference tissue with bone marrow plasma cell infiltration rate, no other significant correlation was observed regarding the rest of the 18 F-NaF PET parameters. Survival analysis revealed that patients with a pathologic 18 F-NaF PET/CT have a shorter PFS than those with a physiologic scan. However, no quantitative 18 F-NaF PET parameter affected PFS. In contrast, the quantitative parameters SUV max , V B , k 3 and influx from reference tissue as well as SUV average from MM lesions derived from 18 F-FDG PET/CT adversely affect PFS. Although further studies are required, the herein presented findings highlight the rather limited role of 18 F-NaF PET/CT, evaluated by means of quantitative analysis based on SUV calculations and two-tissue compartment modeling, in MM survival prognosis. Based on these and previously published results, the application of 18 F-NaF PET/CT as a single PET approach in MM is not recommended. It should be noted, however, that 18 F-NaF can provide essential information on bone remodeling and the patient’s skeletal history, and thus it could be performed in addition to validated imaging techniques, according to clinical indication.
Author Contributions
C.S. performed the PET/CT studies and evaluations, analyzed the data, and drafted the manuscript; A.K.-S. performed the statistical analysis; M.M. was involved in the management of the patients and analyzed the data; A.J. performed the FISH analysis; M.-S.R. was involved in the management of the patients and contributed to data interpretation; H.G. designed the study, was involved in the management of the patients, analyzed the data and revised the manuscript; A.D.-S. designed the study, performed the PET/CT evaluations and revised the manuscript. All authors have read and agreed to the published version of the manuscript.
Funding
The study was part of a special research area project (SFB TRR 79) funded by the German Research Foundation and the Dietmar-Hopp-Foundation.
Conflicts of Interest
The authors declare no conflict of interest.
References
1. Zamagni E. Patriarca F. Nanni C. Zannetti B. Englaro E. Pezzi A. Tacchetti P. Buttignol S. Perrone G. Brioli A. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation Blood 2011 118 5989 5995 10.1182/blood-2011-06-361386 21900189
2. Bartel T.B. Haessler J. Brown T.L. Shaughnessy J.D. Jr. van Rhee F. Anaissie E. Alpe T. Angtuaco E. Walker R. Epstein J. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma Blood 2009 114 2068 2076 10.1182/blood-2009-03-213280 19443657 PMC2744568
3. van Lammeren-Venema D. Regelink J.C. Riphagen I.I. Zweegman S. Hoekstra O.S. Zijlstra J.M. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review Cancer 2012 118 1971 1981 10.1002/cncr.26467 21887677
4. Cavo M. Terpos E. Nanni C. Moreau P. Lentzsch S. Zweegman S. Hillengass J. Engelhardt M. Usmani S.Z. Vesole D.H. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group Lancet. Oncol. 2017 18 e206 e217 10.1016/S1470-2045(17)30189-4 28368259
5. Rajkumar S.V. Dimopoulos M.A. Palumbo A. Blade J. Merlini G. Mateos M.V. Kumar S. Hillengass J. Kastritis E. Richardson P. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet. Oncol. 2014 15 e538 e548 10.1016/S1470-2045(14)70442-5 25439696
6. Rasche L. Angtuaco E. McDonald J.E. Buros A. Stein C. Pawlyn C. Thanendrarajan S. Schinke C. Samant R. Yaccoby S. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma Blood 2017 130 30 34 10.1182/blood-2017-03-774422 28432222 PMC5501152
7. Sachpekidis C. Goldschmidt H. Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma Molecules 2019 25 134 10.3390/molecules25010134 PMC6982887 31905752
8. Zamagni E. Cavo M. The role of imaging techniques in the management of multiple myeloma Br. J. Haematol. 2012 159 499 513 10.1111/bjh.12007 22881361
9. Nanni C. Versari A. Chauvie S. Bertone E. Bianchi A. Rensi M. Bellò M. Gallamini A. Patriarca F. Gay F. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): Final results. IMPeTUs (Italian myeloma criteria for PET USe) Eur. J. Nucl. Med. Mol. Imaging 2018 45 712 719 10.1007/s00259-017-3909-8 29270787
10. Hawkins R.A. Choi Y. Huang S.C. Hoh C.K. Dahlbom M. Schiepers C. Satyamurthy N. Barrio J.R. Phelps M.E. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET J. Nucl. Med. 1992 33 633 642 1569473
11. Grant F.D. Fahey F.H. Packard A.B. Davis R.T. Alavi A. Treves S.T. Skeletal PET with 18 F-fluoride: Applying new technology to an old tracer J. Nucl. Med. 2008 49 68 78 10.2967/jnumed.106.037200 18077529
12. Czernin J. Satyamurthy N. Schiepers C. Molecular mechanisms of bone 18F-NaF deposition J. Nucl. Med. 2010 51 1826 1829 10.2967/jnumed.110.077933 21078790 PMC3169430
13. Segall G. Delbeke D. Stabin M.G. Even-Sapir E. Fair J. Sajdak R. Smith G.T. SNM. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0 J. Nucl. Med. 2010 51 1813 1820 10.2967/jnumed.110.082263 21051652
14. Beheshti M. Mottaghy F.M. Payche F. Behrendt F.F. Van den Wyngaert T. Fogelman I. Strobel K. Celli M. Fanti S. Giammarile F. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging Eur. J. Nucl. Med. Mol. Imaging 2015 42 1767 1777 10.1007/s00259-015-3138-y 26201825
15. Hillner B.E. Siegel B.A. Hanna L. Duan F. Quinn B. Shields A.F. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: Results from the National Oncologic PET Registry J. Nucl. Med. 2015 56 222 228 10.2967/jnumed.114.150391 25593113
16. Sachpekidis C. Goldschmidt H. Hose D. Pan L. Cheng C. Kopka K. Haberkorn U. Dimitrakopoulou-Strauss A. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: Comparison of distribution patterns and tracers’ pharmacokinetics Eur. J. Nucl. Med. Mol. Imaging 2014 41 1343 1353 10.1007/s00259-014-2721-y 24562650
17. Ak İ. Onner H. Akay O.M. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT Ann. Hematol. 2015 94 1567 1575 10.1007/s00277-015-2410-3 26068066
18. Sachpekidis C. Hillengass J. Goldschmidt H. Anwar H. Haberkorn U. Dimitrakopoulou-Strauss A. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma Am. J. Nucl. Med. Mol. Imaging 2017 7 148 156 28913153 PMC5596317
19. Sachpekidis C. Hillengass J. Goldschmidt H. Wagner B. Haberkorn U. Kopka K. Dimitrakopoulou-Strauss A. Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation Eur. J. Nucl. Med. Mol. Imaging 2017 44 50 62 10.1007/s00259-016-3502-6 27573638
20. Nishiyama Y. Tateishi U. Shizukuishi K. Shishikura A. Yamazaki E. Shibata H. Yoneyama T. Ishigatsubo Y. Inoue T. Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: Initial experience Ann. Nucl. Med. 2013 27 78 83 10.1007/s12149-012-0647-7 22914967
21. Wang Y. Yee A.J. Sirard C. Landau S. Raje N. Mahmood U. Sodium fluoride PET imaging as a quantitative pharmacodynamic biomarker for bone homeostasis during anti-DKK1 therapy for multiple myeloma Blood Cancer J. 2017 7 e615 10.1038/bcj.2017.95 28984867 PMC5678221
22. Withofs N. Beguin Y. Cousin F. Tancredi T. Simoni P. Alvarez-Miezentseva V. De Prijck B. Hafraoui K. Bonnet C. Baron F. Dual-tracer PET/CT scan after injection of combined [ 18 F]NaF and [ 18 F]FDG outperforms MRI in the detection of myeloma lesions Hematol. Oncol. 2019 37 193 201 10.1002/hon.2600 30821017
23. Zirakchian Zadeh M. Ostergaard B. Mehdizadeh Seraj S. Ayubcha C. Raynor W. Gerke O. Constantinescu C. Werner T. Zhuang H. Hoilund-Carlsen P.F. Evaluation of myeloma bone disease by means of 18F-sodium fluoride PET/CT J. Nucl. Med. 2019 60 24
24. International Myeloma Working Group Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group Br. J. Haematol. 2003 121 749 757 10.1046/j.1365-2141.2003.04355.x 12780789
25. Goldschmidt H. Mai E.K. Dürig J. Scheid C. Weisel K.C. Kunz C. Bertsch U. Hielscher T. Munder M. Lindemann H.-W. Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial Blood 2017 130 Suppl. 1 400 Available online: http://www.bloodjournal.org/content/130/Suppl_1/400 (accessed on 24 June 2018)
26. Sachpekidis C. Merz M. Kopp-Schneider A. Jauch A. Raab M.S. Sauer S. Hillengass J. Goldschmidt H. Dimitrakopoulou-Strauss A. Quantitative dynamic 18F-fluorodeoxyglucose positron emission tomography/computed tomography before autologous stem cell transplantation predicts survival in multiple myeloma Haematologica. 2019 104 e420 e423 10.3324/haematol.2018.213041 30765474 PMC6717572
27. Dimitrakopoulou-Strauss A. Pan L. Strauss L.G. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients Cancer Imaging 2012 12 283 289 10.1102/1470-7330.2012.0033 23033440 PMC3485644
28. PMOD Technologies Available online: http://www.pmod.com/files/download/v31/doc/pbas/4729.htm (accessed on 16 January 2020)
29. Mikolajczyk K. Szabatin M. Rudnicki P. Grodzki M. Burger C. A Java environment for medical image data analysis: Initial application for brain PET quantitation Med. Inform. 1998 23 207 214 10.3109/14639239809001400 9785322
30. Burger C. Buck A. Requirements and implementations of a flexible kinetic modeling tool J. Nucl. Med. 1997 38 1818 1823 9374364
31. Pan L. Cheng C. Haberkorn U. Dimitrakopoulou-Strauss A. Machine learning-based kinetic modeling: A robust and reproducible solution for quantitative analysis of dynamic PET data Phys. Med. Biol. 2017 62 3566 3581 10.1088/1361-6560/aa6244 28379842
32. Ohtake T. Kosaka N. Watanabe T. Yokoyama I. Moritan T. Masuo M. Iizuka M. Kozeni K. Toshimitsu Momose T. Oku S. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs J. Nucl. Med. 1991 32 1432 1438 2066802
33. Dimitrakopoulou-Strauss A. Pan L. Sachpekidis C. Kinetic modeling and parametric imaging with dynamic PET for oncological applications: General considerations, current clinical applications, and future perspectives Eur. J. Nucl. Med. Mol. Imaging. 2020 10.1007/s00259-020-04843-6 PMC7835173 32430580
34. Dimitrakopoulou-Strauss A. Strauss L.G. Mikolajczyk K. Burger C. Lehnert T. Bernd L. Ewerbeck V. On the fractal nature of positron emission tomography (PET) studies World J. Nucl. Med. 2003 4 306 313 Available online: https://inis.iaea.org/search/search.aspx?orig_q = RN:34087347 (accessed on 12 January 2020)
35. Sachpekidis C. Mai E.K. Goldschmidt H. Hillengass J. Hose D. Pan L. Haberkorn U. Dimitrakopoulou-Strauss A. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: Patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate Clin. Nucl. Med. 2015 40 e300 e307 10.1097/RLU.0000000000000773 25783508
36. Palumbo A. Avet-Loiseau H. Oliva S. Lokhorst H.M. Goldschmidt H. Rosinol L. Richardson P. Caltagirone S. Lahuerta J.J. Facon T. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group J. Clin. Oncol. 2015 33 2863 2869 10.1200/JCO.2015.61.2267 26240224 PMC4846284
37. Neben K. Lokhorst H.M. Jauch A. Bertsch U. Hielscher T. van der Holt B. Salwender H. Blau I.W. Weisel K. Pfreundschuh M. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p Blood 2012 119 940 948 10.1182/blood-2011-09-379164 22160383
38. Lapa C. Knop S. Schreder M. Rudelius M. Knott M. Jörg G. Samnick S. Herrmann K. Buck A.K. Einsele H. 11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement Theranostics 2016 6 254 261 10.7150/thno.13921 26877783 PMC4729773
39. Lapa C. Schreder M. Lückerath K. Samnick S. Rudelius M. Buck A.K. Kortüm K.M. Einsele H. Rosenwald A. Knop S. [11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions Br. J. Haematol. 2018 181 701 703 10.1111/bjh.14696 28466502
40. Lapa C. Garcia-Velloso M.J. Lückerath K. Samnick S. Schreder M. Otero P.R. Schmid J.S. Herrmann K. Knop S. Buck A.K. 11C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions Theranostics 2017 7 2956 2964 10.7150/thno.20491 28824728 PMC5562228
41. Da Vià M.C. Solimando A.G. Garitano-Trojaola A. Barrio S. Munawar U. Strifler S. Haertle L. Rhodes N. Teufel E. Vogt C. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement Oncologist 2020 25 112 118 10.1634/theoncologist.2019-0356 32043788 PMC7011664
42. Philipp-Abbrederis K. Herrmann K. Knop S. Schottelius M. Eiber M. Lückerath K. Pietschmann E. Habringer S. Gerngroß C. Franke K. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma EMBO. Mol. Med. 2015 7 477 487 10.15252/emmm.201404698 25736399 PMC4403048
43. Pan Q. Cao X. Luo Y. Li J. Feng J. Li F. Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: Comparison to 18F-FDG PET/CT Eur. J. Nucl. Med. Mol. Imaging 2020 47 537 546 10.1007/s00259-019-04605-z 31776631
44. Lapa C. Herrmann K. Schirbel A. Hänscheid H. Lückerath K. Schottelius M. Kircher M. Werner R.A. Schreder M. Samnick S. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma Theranostics 2017 7 1589 1597 10.7150/thno.19050 28529638 PMC5436514
45. Varettoni M. Corso A. Pica G. Mangiacavalli S. Pascutto C. Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: A longitudinal study on 1003 consecutive patients Ann. Oncol. 2010 21 325 330 10.1093/annonc/mdp329 19633044
46. Hall M.N. Jagannathan J.P. Ramaiya N.H. Shinagare A.B. Van den Abbeele A.D. Imaging of extraosseous myeloma: CT, PET/CT, and MRI features AJR. Am. J. Roentgenol. 2010 195 1057 1065 10.2214/AJR.10.4384 20966307
47. Turkbey B. Tan E. Korde N. Kwok M. Manasanch E.E. Tageja N. Mailankody S. Roschewski M. Mulquin M. Carpenter A. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: A prospective study using functional and morphologic imaging Leuk. Lymphoma. 2016 57 1114 1121 10.3109/10428194.2015.1090572 26690712 PMC5576169
48. Esteve F. Roodman G.D. Pathophysiology of myeloma bone disease Best Pract Res. Clin. Haematol. 2007 20 613 624 10.1016/j.beha.2007.08.003 18070709
49. Nakuz T.S. Millinger F.P. El-Rabadi K. Weber M. Pichler V. Wadsak W. Mitterhauser M. Haug A. Hacker M. Karanikas G. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using 18F-FDG-PET/CT and 18F-NaF-PET/CT Anticancer Res. 2019 39 1943 1952 10.21873/anticanres.13304 30952737
50. Zirakchian Zadeh M. Østergaard B. Raynor W.Y. Revheim M.E. Seraj S.M. Acosta-Montenegro O. Ayubcha C. Yellanki D.P. Al-Zaghal A. Nielsen A.L. Comparison of 18 F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy [published online ahead of print, 2020 Apr 3] Eur. J. Nucl. Med. Mol. Imaging 2020 10.1007/s00259-020-04768-0 32246208
51. Zhang X. Xie Z. Berg E. Judenhofer M.S. Liu W. Xu T. Ding Y. Lv Y. Dong Y. Deng Z. Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER J. Nucl. Med. 2020 61 285 291 10.2967/jnumed.119.230565 31302637 PMC8801950